Skip to main content

Market Overview

Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target

Share:

In a report published Wednesday, CRT Capital analyst Tim Chiang increased his price target on Buy-rated shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) to $220 from a previous $180 following Tuesday's conference call, which highlighted strong fundamentals and the strategic rationale behind the acquisition of Salix Pharmaceuticals, Ltd (NASDAQ: SLXP) and Dendreon.

"In addition to both deals adding new product segments to Valeant's top line (GI and Oncology) we believe these transactions play into Valeant's strengths in the integration arena focused on lowering costs and increasing profitability," Chiang wrote.

Chiang added that in the case of Salix, Valeant intends to work down wholesaler inventory levels to two months or less by the end of the year. In the case of Dendreon, Valeant intends to increase gross margins to approximately 65 percent (from approximately 50 percent) by the end of 2015.

Shares traded recently at $197.64, down 2.1 percent.

Latest Ratings for VRX

DateFirmActionFromTo
Jun 2018TD SecuritiesDowngradesBuyHold
Jun 2018BarclaysUpgradesEqual-WeightOverweight
May 2018MizuhoUpgradesNeutralBuy

View More Analyst Ratings for VRX

View the Latest Analyst Ratings

 

Related Articles (VRX)

View Comments and Join the Discussion!

Posted-In: Dendreon oncology Pharamceuticals Tim ChiangAnalyst Color Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com